Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion Study of [14C] Golcadomide in Healthy Males
NCT05567510Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of golcadomide in non-Hodgkin lymphoma (NHL), sponsored by Bristol Myers Squibb. Primary endpoints: Total radioactivity recovered in whole blood up to 22 days, Total radioactivity recovered in plasma up to 22 days and 7 more. Started Oct 2022; status: completed.
02
Drugs
golcadomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05567510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567510.